After a Decade-Long ‘War on Vaping,’ Is the FDA Finally Embracing Tobacco Harm Reduction?

Home Politics America After a Decade-Long ‘War on Vaping,’ Is the FDA Finally Embracing Tobacco...

After a Decade-Long ‘War on Vaping,’ Is the FDA Finally Embracing Tobacco Harm Reduction?

After years of PMTA denials and regulatory battles, Bret Koplow’s appointment raises hopes of a more risk-proportionate approach to nicotine.

After almost a decade of conflict between the U.S. Food and Drug Administration (FDA) and the vaping industry, there are signs that America’s approach to tobacco harm reduction could be entering a distinct phase.

He described FDA policy as a sustained “war on vaping” that has restricted products, burdened independent manufacturers and contributed to public confusion about the relative risks of vaping and smoking.

But the appointment of Bret Koplow, Ph.D., J.D., as permanent director of the Center for Tobacco Products (CTP) could indicate a more pragmatic direction—one that combines strict youth protection with greater recognition of lower-risk alternatives for adults who smoke.

Political alarm over youth vaping, the rise and subsequent regulatory problems of Juul, and FDA prevention initiatives such as “The Genuine Cost” campaign further transformed vaping from a relatively small regulatory issue into a major public-health and political battle.

Political alarm over youth vaping, the rise and subsequent regulatory problems of Juul, and FDA prevention initiatives such as “The Actual Cost” campaign further transformed vaping from a relatively modest regulatory issue into a major public-health and political battle.

That concern has significance beyond the vaping industry because smokers’ decisions depend partly on whether they understand that the primary danger from cigarettes comes from inhaling the products of combustion.

Independent evidence increasingly supports vaping’s role in helping smokers leave cigarettes behind.

The latest Cochrane living review found high-certainty evidence that nicotine vapes produce higher smoking-cessation rates than nicotine replacement therapy, reinforcing the argument that access to regulated vaping products can have a legitimate public-health role.

Koplow, who had already been acting CTP director , has now been given the position permanently.

According to the Department of Health and Human Services (HHS), his responsibilities will contain promoting innovation and access to less harmful alternatives for adults who smoke while protecting young individuals from nicotine and tobacco use.

That language reflects the fundamental balance tobacco harm reduction advocates have long requested: differentiate products by risk while preventing youth uptake.

Koplow said accurate information about relative harms could support adult smokers make informed decisions.

The agency had previously authorised another six nicotine pouch products through an accelerated review pilot, with Koplow explicitly describing them as lower-risk alternatives that expand options for adults who smoke.

In May 2026, the FDA authorised fruit-flavoured e-cigarettes for adult smokers for the first duration.

The decision suggests a regulatory model in which innovation could address competing objectives: preserving products that may appeal to adult smokers while using technological safeguards to restrict youth access.

In May, he argued that more efficient reviews could allow products meeting the required public-health standard to reach adults who could use them to reduce their risk of premature death and chronic disease.

The emerging philosophy therefore looks less like deregulation and more like risk-proportionate regulation: facilitate scientifically supported alternatives for adult smokers while acting aggressively against products and marketing practices that threaten youth.

The FDA regulates a market in which cigarettes—the most dangerous widely used nicotine product—coexist with non-combustible alternatives capable of delivering nicotine without burning tobacco. A coherent regulatory system should recognise those differences while ensuring that products intended for grown-up smokers do not create unnecessary risks for children.

Koplow’s appointment does not guarantee a revolution in FDA tobacco policy.

After years in which the FDA was seen as waging a “war on vaping ,” the more consequential question may now be whether the agency is finally prepared to make tobacco harm reduction a central part of its strategy for ending smoking-related disease.

Get news and current headlines about vaping every Friday.

In-house journalist covering international vaping news.